Cargando…

Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori

AIM: To evaluate the eradication rate, safety, and compliance of minocycline-containing bismuth quadruple regimens in patients with an untreated Helicobacter pylori (H. pylori) infection. METHODS: A total of 360 patients with an untreated H. pylori infection were enrolled in this study between June...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lingyun, Lan, Yu, Wang, Qi, Zhang, Yuexia, Si, Xiaobei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942845/
https://www.ncbi.nlm.nih.gov/pubmed/31933634
http://dx.doi.org/10.1155/2019/9251879
_version_ 1783484783008940032
author Zhang, Lingyun
Lan, Yu
Wang, Qi
Zhang, Yuexia
Si, Xiaobei
author_facet Zhang, Lingyun
Lan, Yu
Wang, Qi
Zhang, Yuexia
Si, Xiaobei
author_sort Zhang, Lingyun
collection PubMed
description AIM: To evaluate the eradication rate, safety, and compliance of minocycline-containing bismuth quadruple regimens in patients with an untreated Helicobacter pylori (H. pylori) infection. METHODS: A total of 360 patients with an untreated H. pylori infection were enrolled in this study between June 2017 and October 2018. Patients were randomly divided into a minocycline/amoxicillin (RMAB) group, a minocycline/metronidazole (RMMB) group, or an amoxicillin/clarithromycin (RACB) group, and all groups received a combined treatment approach with rabeprazole and bismuth to create a quadruple regimen for 14 days. A 3 to 5-day follow-up was adopted to evaluate the safety and compliance of medications after medicine administration. (13)C-urea breath test was performed to confirm the eradication of H. pylori 4-12 weeks after therapy. RESULTS: No significant differences were observed at baseline data among the three groups (p > 0.05). Based on the intent-to-treat analysis, the eradication rates of the RMAB group, RMMB group, and RACB control group were 85.7% (102/119), 77.1% (91/118), and 71.7% (86/120), respectively, with significant difference (χ(2) = 7.015, p = 0.030). According to per protocol analysis, the eradication rates of RMAB group, RMMB group, and RACB group were 89.5% (102/114), 84.3% (91/108), and 76.8% (86/112), respectively, with statistically significant differences (χ(2) = 6.673, p = 0.036). The eradication rates of the RMAB group and RACB group were significantly different (p < 0.05). The overall incidences of adverse events in the three groups were 30.0%, 37.5%, and 40.0%, respectively (p > 0.05). Nausea, epigastric discomfort, and dizziness were more obvious in patients in the RMMB group compared to the other two groups (p < 0.05). Moreover, two patients discontinued due to severe dizziness and nausea in the RMMB group. A taste disorder was more prominent in patients in the RACB group compared to patients in the other two groups (p < 0.05), and one patient discontinued because of the bitterness in the mouth. Soon after discontinuation of the medicine, all adverse events disappeared. Conclusion. The bismuth quadruple regimen using minocycline/amoxicillin showed a better eradication effect with fewer side effects in patients with untreated H. pylori infections. The bismuth quadruple regimen with minocycline/metronidazole had a good eradication effect with more obvious side effects and might be recommended to patients with penicillin allergy.
format Online
Article
Text
id pubmed-6942845
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-69428452020-01-13 Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori Zhang, Lingyun Lan, Yu Wang, Qi Zhang, Yuexia Si, Xiaobei Gastroenterol Res Pract Research Article AIM: To evaluate the eradication rate, safety, and compliance of minocycline-containing bismuth quadruple regimens in patients with an untreated Helicobacter pylori (H. pylori) infection. METHODS: A total of 360 patients with an untreated H. pylori infection were enrolled in this study between June 2017 and October 2018. Patients were randomly divided into a minocycline/amoxicillin (RMAB) group, a minocycline/metronidazole (RMMB) group, or an amoxicillin/clarithromycin (RACB) group, and all groups received a combined treatment approach with rabeprazole and bismuth to create a quadruple regimen for 14 days. A 3 to 5-day follow-up was adopted to evaluate the safety and compliance of medications after medicine administration. (13)C-urea breath test was performed to confirm the eradication of H. pylori 4-12 weeks after therapy. RESULTS: No significant differences were observed at baseline data among the three groups (p > 0.05). Based on the intent-to-treat analysis, the eradication rates of the RMAB group, RMMB group, and RACB control group were 85.7% (102/119), 77.1% (91/118), and 71.7% (86/120), respectively, with significant difference (χ(2) = 7.015, p = 0.030). According to per protocol analysis, the eradication rates of RMAB group, RMMB group, and RACB group were 89.5% (102/114), 84.3% (91/108), and 76.8% (86/112), respectively, with statistically significant differences (χ(2) = 6.673, p = 0.036). The eradication rates of the RMAB group and RACB group were significantly different (p < 0.05). The overall incidences of adverse events in the three groups were 30.0%, 37.5%, and 40.0%, respectively (p > 0.05). Nausea, epigastric discomfort, and dizziness were more obvious in patients in the RMMB group compared to the other two groups (p < 0.05). Moreover, two patients discontinued due to severe dizziness and nausea in the RMMB group. A taste disorder was more prominent in patients in the RACB group compared to patients in the other two groups (p < 0.05), and one patient discontinued because of the bitterness in the mouth. Soon after discontinuation of the medicine, all adverse events disappeared. Conclusion. The bismuth quadruple regimen using minocycline/amoxicillin showed a better eradication effect with fewer side effects in patients with untreated H. pylori infections. The bismuth quadruple regimen with minocycline/metronidazole had a good eradication effect with more obvious side effects and might be recommended to patients with penicillin allergy. Hindawi 2019-12-18 /pmc/articles/PMC6942845/ /pubmed/31933634 http://dx.doi.org/10.1155/2019/9251879 Text en Copyright © 2019 Lingyun Zhang et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhang, Lingyun
Lan, Yu
Wang, Qi
Zhang, Yuexia
Si, Xiaobei
Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
title Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
title_full Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
title_fullStr Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
title_full_unstemmed Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
title_short Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
title_sort application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of helicobacter pylori
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942845/
https://www.ncbi.nlm.nih.gov/pubmed/31933634
http://dx.doi.org/10.1155/2019/9251879
work_keys_str_mv AT zhanglingyun applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori
AT lanyu applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori
AT wangqi applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori
AT zhangyuexia applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori
AT sixiaobei applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori